Atty. Docket No.:

PATENT 16 16 Segn

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplication of:

Communi, et al.

Serial No.:

09/077,173

Filed:

November 12, 1998

Entitled:

"Human Pyrimidine Receptor"

Examiner:

Group Art Unit:

1646

Conf. No.:

5692

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Box: Sequence Listing, P.O. Box 2327, Arlington, VA 22202.

Kathleen M. Williams

Name of Person Mailing Raper

Signature of Person Mailing Paper

U.S. Patent & Trademark Office

Box: Sequence P.O. Box 2327

Arlington, VA 22202

FEB 2 6 2003

TRANSMITTAL LETTER

TECH CENTER 1600/2900

Enclosed for filing the above-identified patent application, please find the following documents:

- 1. Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
- Copy of Notice to Comply; 2.
- Paper copy of Sequence Listing: 3.
- Computer readable copy of the Sequence Listing; 4.
- Statement under 37 C.F.R. § 1.821(f) and (g); and 5.
- Return Post Card. 6.

The Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference 9409/2112. A duplicate of this transmittal letter is enclosed for this purpose.

February 13, 2003 Date:

Respectfully submitted,


Kathleen M. Williams

Registration No.: 34,380 Customer No.: 29933

Palmer & Dodge LLP 111 Huntington Avenue

Boston, MA 02199-7613

Tel: 617-239-0100





Atty. Docket No.:

9409/2112

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Communi, et al.

Serial No.:

09/077,173

Filed:

November 12, 1998

Entitled:

"Human Pyrimidine Receptor"

Examiner:

J. F. Murphy

Group Art Unit:

1646

Conf. No.:

5692

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Box: Sequence Listing, P.O. Box 2327, Arlington, VA 22202.

Kathleen M. Williams

Name of Person Mailing Paper

Signature of Person Mailing Paper

U.S. Patent & Trademark Office

Box: Sequence P.O. Box 2327

Arlington, VA 22202

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Sir:

A corrected sequence listing is submitted in response to the Notice to Comply With Requirements For Patent Applications Containing Nucleotide And/Or Amino Acid Sequence Disclosures mailed by the PTO on January 15, 2003.

The Notice stated that a copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. §§ 1.822 and/or 1.823.

Enclosed please find a Paper Copy of the Sequence Listing, a Computer Readable Copy of the Sequence Listing, and the Statement under 37 C.F.R. § 1.821(f) and (g).

Kindly replace the existing paper copy of the sequence listing with the enclosed substitute paper copy.

Date:

February /3, 2003

Respectfully submitted/

Name: Kathleen M. Williams

Registration No.: 34,380

Customer No.: 29933 Palmer & Dodge LLP

111 Huntington Avenue Boston, MA 02199-7613

Tel: 617-239-0100

RECEIVED

FEB **2 6** 2003

TECH CENTER 1600/2900

27/3 1.9.1 2/2/2 Application No.: 091673137

ANTENDETICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

Ĺ.	 This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	 This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
<u> </u>	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
ij	7. Other:
	7. Other:
∏ Ap	7. Other:
Ap	7. Other: RECEIVED Provide: FEB 2 6 2003 An initial or substitute computer readable form (CRE) copy of the "Sequence Link" (CRE).
Ap	FER O
Ap	7. Other: PECE/VEL Policant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing" CENTER 1600/2900 An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
	An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry
	An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For	An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). Questions regarding compliance to these requirements, please contact:
For	An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification. A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE